A trial of BMS-986012 in combination with chemotherapy for small cell lung cancer
Phase 1
- Conditions
- Extensive-Stage Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2024-511824-15-00
- Lead Sponsor
- Bristol Myers Squibb International Corporation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
Pulmonary SCLC documented by histology or cytology, Extensive disease (Stage IV) Small Cell Lung Cancer, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, Male and Females 18 years of age or older
Exclusion Criteria
Prior systemic therapy for lung cancer, Symptomatic brain metastases, Grade 2 peripheral neuropathy, Active or chronic infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV), Other active malignancies or prior malignancy within 2 years
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method